Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2021 | Key debates from the St Gallen Expert Consensus

Sherene Loi, MBBS, PhD, FRACP, FAHMS, Peter MacCallum Cancer Centre at the University of Melbourne, Melbourne, Australia, shares her highlights from the St Gallen International Expert Consensus 2021. Prof. Loi notes the debates surrounding anthracycline omission in HER2-positive breast cancer as an important development, as well as discussions on the importance of chemotherapy for premenopausal women with hormone-responsive breast cancer. This interview took place during the 17th St. Gallen International Breast Cancer Conference.


Research funding to institution: Novartis, Bristol Meyers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics Astra Zeneca, Roche-Genentech, Seattle Genetics.
Consultancy (not compensated): Seattle Genetics, Novartis, Bristol Meyers Squibb, Merck, AstraZeneca, Roche-Genentech.
Consultancy (paid to institution): Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, Astra Zeneca, Silverback Therapeutics, G1 Therapeutics, PUMA Biotechnologies, Seattle Genetics, Bristol Meyers Squibb.
Scientific Advisory Board Member: Akamara Therapeutics.
Supported by the National Breast Cancer Foundation of Australia Endowed Chair and the Breast Cancer Research Foundation, New York.